1. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity;Llerena;Pharmacogenomics,2009
2. Polymorphic hydroxylation of debrisoquine in man;Mahgoub;Lancet,1977
3. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect;Eichelbaum;Eur. J. Clin. Pharmacol.,1979
4. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans;Eiermann;Drug Metab. Dispos.,1998
5. Technology platforms for pharmacogenomic diagnostic assays;Koch;Nat. Rev. Drug Discov.,2004